Evercore ISI Forecasts Strong Price Appreciation for Cardinal Health (NYSE:CAH) Stock

Cardinal Health (NYSE:CAHGet Free Report) had its price target raised by investment analysts at Evercore ISI from $250.00 to $260.00 in a research report issued to clients and investors on Friday,MarketScreener reports. Evercore ISI’s price target would indicate a potential upside of 14.61% from the stock’s previous close.

CAH has been the topic of several other reports. Wells Fargo & Company boosted their target price on Cardinal Health from $221.00 to $237.00 and gave the stock an “overweight” rating in a report on Thursday, January 15th. Argus boosted their price objective on Cardinal Health from $211.00 to $232.00 and gave the stock a “buy” rating in a research note on Friday, January 23rd. Leerink Partners upped their target price on Cardinal Health from $240.00 to $268.00 and gave the company an “outperform” rating in a report on Thursday. TD Cowen reaffirmed a “buy” rating on shares of Cardinal Health in a research note on Tuesday, January 27th. Finally, Citigroup raised shares of Cardinal Health from a “neutral” rating to a “buy” rating and boosted their price target for the company from $190.00 to $244.00 in a research report on Friday, January 9th. Fifteen equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $241.27.

Check Out Our Latest Stock Analysis on CAH

Cardinal Health Stock Down 0.1%

Shares of CAH opened at $226.85 on Friday. The firm’s fifty day moving average is $206.92 and its two-hundred day moving average is $180.13. The stock has a market cap of $53.90 billion, a PE ratio of 32.64, a price-to-earnings-growth ratio of 1.51 and a beta of 0.64. Cardinal Health has a 52-week low of $120.72 and a 52-week high of $230.81.

Cardinal Health (NYSE:CAHGet Free Report) last posted its quarterly earnings results on Thursday, February 5th. The company reported $2.63 earnings per share for the quarter, topping the consensus estimate of $2.31 by $0.32. Cardinal Health had a net margin of 0.68% and a negative return on equity of 92.50%. The firm had revenue of $65.63 billion for the quarter, compared to the consensus estimate of $64.88 billion. During the same period last year, the firm posted $1.93 earnings per share. The company’s revenue for the quarter was up 18.8% on a year-over-year basis. As a group, research analysts anticipate that Cardinal Health will post 7.95 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of CAH. Evoke Wealth LLC acquired a new stake in shares of Cardinal Health during the fourth quarter valued at about $327,000. Ignite Planners LLC lifted its holdings in shares of Cardinal Health by 17.0% in the 4th quarter. Ignite Planners LLC now owns 2,125 shares of the company’s stock worth $457,000 after acquiring an additional 309 shares during the last quarter. Axxcess Wealth Management LLC boosted its position in shares of Cardinal Health by 217.1% during the 4th quarter. Axxcess Wealth Management LLC now owns 38,500 shares of the company’s stock worth $7,912,000 after purchasing an additional 26,359 shares during the period. Kingdom Financial Group LLC. acquired a new stake in Cardinal Health in the 4th quarter valued at approximately $72,000. Finally, Global Retirement Partners LLC raised its position in Cardinal Health by 73.3% in the fourth quarter. Global Retirement Partners LLC now owns 6,169 shares of the company’s stock valued at $1,268,000 after purchasing an additional 2,609 shares during the period. Institutional investors and hedge funds own 87.17% of the company’s stock.

More Cardinal Health News

Here are the key news stories impacting Cardinal Health this week:

  • Positive Sentiment: Q2 results and raised outlook — Cardinal reported Q2 FY2026 revenue up ~19% to $65.6B and non‑GAAP EPS of $2.63 (beat), and raised fiscal‑year non‑GAAP EPS guidance to $10.15–$10.35; management cited strong specialty medicine demand and improved segment performance. PR Newswire
  • Positive Sentiment: Analyst upgrade and price‑target lift — Leerink Partners raised its price target from $240 to $268 and kept an outperform rating, signaling more upside from current levels. MarketScreener
  • Positive Sentiment: Street commentary and momentum coverage — Multiple outlets (Barron’s, Reuters, Zacks, TipRanks, 24/7 Wall St.) highlight the beat, raised guidance and accelerating specialty drug volumes, which has driven momentum interest in the stock. Examples: Reuters coverage on the outlook and Barron’s note on guidance lifts. Reuters
  • Neutral Sentiment: Earnings call & transcripts available — Management commentary and slides from the Q2 call confirm the drivers behind the beat (specialty medicine, margin expansion, buybacks); these provide detail but no new surprises beyond the release. MSN Transcript
  • Neutral Sentiment: Momentum stock analysis — Zacks highlights style‑score based momentum attributes, which can attract technical and quant funds but also increase volatility. Zacks
  • Negative Sentiment: Valuation and historical ROE signal — After the rally the stock trades at an elevated P/E (~34x) and company data show a negative trailing return on equity metric, which could concern value‑focused investors and limit upside absent continued execution. Background valuation metrics

Cardinal Health Company Profile

(Get Free Report)

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company’s core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.

Recommended Stories

Analyst Recommendations for Cardinal Health (NYSE:CAH)

Receive News & Ratings for Cardinal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health and related companies with MarketBeat.com's FREE daily email newsletter.